October 10, 2019
HighTide Therapeutics (“HighTide”) and Silexon Tech (“Silexon”) jointly announced a long-term strategic collaboration agreement in new drug research and development.
This partnership will leverage HighTide's rich experience in drug research and clinical development in chronic diseases (especially chronic liver diseases and metabolic diseases), and the unique strength of Silexon in artificial intelligence (AI) / machine learning algorithm tools.
Dr. Liping Liu, founder of HighTide, said: “HighTide has been committed to developing innovative drugs with global competitiveness since its founding in 2011. Two of our drug candidates have entered clinical trials, while discovery of early-stage pipeline continues. We believe our collaboration with Silexon, which has an advanced AI technology and platform, will accelerate and optimize the development of new drugs to meet unmet medical needs and provide personalized treatment solutions for more patients.”
Silexon CEO Hainian Zeng said: "Silexon’s vision is to increase the accessibility of innovative drugs to meet patients and medical needs, improve the efficiency of new drug R&D through AI / machine learning, and reduce development cost. By partnering with HighTide, which has extensive experience in research and development of novel drugs, we will accelerate and optimize the drug R&D process through AI algorithm tools, diversify HighTide’s pipeline, and reduce R&D cost.
About HighTide Therapeutics
HighTide Therapeutics Inc., founded in 2011 in Shenzhen, China, is dedicated to the discovery and development of innovative therapeutics for people suffering from non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs. For additional information, please visit https://hightidetx.com/.
HTD1801, HighTide’s lead program, is a new molecular entity being developed for the treatment of NASH and PSC. HTD1801 has received U.S. Food and Drug Administration Fast Track designation for both NASH and PSC, and FDA Orphan Drug designation for PSC. HTD1801 is currently in Phase 2 proof of concept trials for NASH and PSC in the U.S. Topline clinical results are expected in 2020.
In addition, HighTide has several other pipelines in development for GI and metabolic diseases, including HTD4010 for Pancreatitis.
Silexon was founded in September 2018. It aims to empower drug discovery and development with multi-disciplinary interdisciplinary AI, improving the efficiency of new drug research, and reducing drug development and cost. For more information, please visit http://www.silexon.tech/. Silexon has completed artificial intelligence algorithm construction and verification in virtual high-throughput screening, drug target discovery, old drug new use, and biologics yield optimization, and has managed to screen multiple pre-clinical assets.